The latest price target for XORTX Therapeutics (NASDAQ:XRTX) was reported by Alliance Global Partners on January 4, 2024. The analyst firm set a price target for $14.00 expecting XRTX to rise to within 12 months (a possible 1066.67% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for XORTX Therapeutics (NASDAQ:XRTX) was provided by Alliance Global Partners, and XORTX Therapeutics maintained their buy rating.

There is no last upgrade for XORTX Therapeutics

There is no last downgrade for XORTX Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of XORTX Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for XORTX Therapeutics was filed on January 4, 2024 so you should expect the next rating to be made available sometime around January 4, 2025.

While ratings are subjective and will change, the latest XORTX Therapeutics (XRTX) rating was a maintained with a price target of $9.00 to $14.00. The current price XORTX Therapeutics (XRTX) is trading at is $1.20, which is out of the analyst’s predicted range.